SCHEMBL5136240

SCHEMBL5136240

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1cccc(F)c1F

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
ALDH1A1 P00352 5/20 0.38
TSHR P16473 4/20 0.38
KDM4E B2RXH2 4/20 0.38
CYP3A4 P08684 4/20 0.38
HPGD P15428 4/20 0.38
HSD17B10 Q99714 4/20 0.38
PDE4B Q07343 2/20 0.37
TP53 P04637 2/20 0.37
P2RX7 Q99572 1/20 0.37
HDAC1 Q13547 1/20 0.36
ICMT O60725 2/20 0.35
CNR2 P34972 1/20 0.35
GAA P10253 1/20 0.34
TLR8 Q9NR97 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652221 0.97 C5AR1 (0.42) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5135151 0.95 C5AR1 (0.38) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5135121 0.93 C5AR1 (0.41) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5137577 0.90 C5AR1 (0.43) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5134701 0.89 KDM4E (0.39) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL647986 0.89 C5AR1 (0.43) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5137572 0.88 C5AR1 (0.39) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5135633 0.87 C5AR1 (0.42) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL650029 0.87 C5AR1 (0.40) C5AR1ALDH1A1TSHRKDM4ECYP3A4
SCHEMBL5137131 0.86 C5AR1 (0.41) C5AR1ALDH1A1TSHRKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed